Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 28c, Offers FY Guidance, Approves $5B Buyback
February 6, 2020 7:08 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.22, $0.28 better than the analyst estimate of $0.94. Revenue for the quarter came in at $7.9 billion versus the consensus estimate of $6.19 billion.
Bristol-Myers Squibb maintains a balanced approach to capital allocation focused on future business development and sourcing external innovation as a priority, de-leveraging in the near term to maintain strong investment grade credit ratings and less than 1.5x debt/EBITDA by 2023, planning for annual dividend increases, subject to board... More
